Today’s announcement marks the signing of Trellus Health’s first demonstration project to use its TrellusElevate™ platform amongst a health plan and is in line with the company strategy outlined at IPO. The agreement with Mount Sinai Health System’s employee health plan aims to initially recruit and engage with 25 Inflammatory Bowel Disease (IBD) patients, to provide a framework for future contract expansions in 2022. The project will produce data on patient recruitment, engagement and programme satisfaction that may be leveraged in future contractual negotiations with other health plans. It is a significant first milestone and supports our financial estimates and the anticipation that Trellus Health will be generating revenue in the current year. We continue to anticipate an inflection in revenues from FY’22 driven by further demonstration project agreements that expected to be agreed in the coming months. We reiterate that the scalability of the opportunity within IBD and other chronic conditions remains highly compelling.
